Table 2.
Measure | Age-restricted subjects* |
P value | ||
---|---|---|---|---|
HIV infected (n = 309) | Control (n = 187) | All (n = 496) | ||
Diabetes (2 h >200 mg/dL), % (n) | 1.3 (4/309) | 0 (0/187) | 0.65 | |
OR for HIV+ vs. control subjects (95% CI) | NA | |||
IGT (2 h >140 mg/dL), % (n) | 16.8 (52/309) | 12.3 (23/187) | ||
OR for HIV+ vs. control subjects (95% CI) | ||||
Unadjusted | 1.44 (0.85–2.45) | 0.17 | ||
Adjusted for demographics | 1.32 (0.76–2.30) | 0.33 | ||
Final model with AT** | 0.84 (0.44–1.62) | 0.61 | ||
IGT (2 h >140 mg/dL) in those without IFG100, % (n)‡ | 13.1 (33/252) | 8.2 (12/146) | ||
OR for HIV+ vs. control subjects (95% CI) | ||||
Unadjusted | 1.68 (0.84–3.37) | 0.14 | ||
Adjusted for demographics | 1.61 (0.78–3.33) | 0.20 | ||
Final model with AT** | 1.14 (0.50–2.59) | 0.76 | ||
2-h glucose (mg/dL) | ||||
Median (IQR) | 105.0 (83–128) | 96.3 (78.3–121.3) | ||
Mean ± SD | 108.9 ± 35.9 | 101.3 ± 32.7 | ||
Mean difference HIV+ vs. control subjects (95% CI) | ||||
Unadjusted | 7.6 (1.7–13.6) | 0.012 | ||
Adjusted for demographics | 7.3 (1.0–13.5) | 0.023 | ||
Final model with AT** | 4.3 (−2.3 to 10.8) | 0.20 |
P values in boldface denote statistical significance at P < 0.05. Those with fasting glucose ≥126 mg/dL or taking diabetes medication are excluded. IQR, interquartile range; OR, odds ratio.
*All analyses are age restricted to 38–52 years.
**Final model adjusts for demographics and AT.
‡IFG100 is defined as fasting glucose >100 mg/dL.